MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Clinical trial NCT01273181 · TERMINATED
Trial details
- NCT number
- NCT01273181
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-12-01
- Primary completion
- 2012-12-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.